Expert Interview
Evaluating BridgeBio's (BBIO) Phase 3 ATTRibute-CM Trial Results for Attruby (Acoramidis) in ATTR-CM Patients
Ticker(s): BBIOA cardiologist specializing in amyloidosis and heart failure management, with expertise in evaluating novel therapies and understanding their role in reducing cardiovascular morbidity and mortality. The expert should have insights into the challenges of treating ATTR-CM and familiarity with TTR stabilization mechanisms.
Attruby achieves ≥90% TTR stabilization, the highest reported to date. How does this level of stabilization translate into clinical benefits for ATTR-CM patients compared to existing treatments?
Added By: slingshot_insightsThe ATTRibute-CM trial demonstrated a separation in cardiovascular outcomes as early as three months. What does this rapid onset of benefit suggest about the mechanism of action and potential real-world impact of Attruby?
Added By: slingshot_insightsAttruby reduced composite cardiovascular mortality and hospitalization by 42% at Month 30. How transformative are these findings for patients with ATTR-CM, particularly those with limited options?
Added By: slingshot_insightsImprovements in 6-minute walk distance, Kansas City Cardiomyopathy Questionnaire scores, and NT-proBNP were observed. How do these measures reflect on the overall efficacy and quality-of-life improvements for patients?
Added By: slingshot_insightsAttruby showed a mild safety profile, with common side effects such as diarrhea resolving without discontinuation. How does this profile position it as a first-line treatment for ATTR-CM?
Added By: slingshot_insightsIn a crowded therapeutic space for ATTR-CM, how does Attruby’s mechanism of mimicking the T119M rescue mutation differentiate it from other stabilizers or emerging therapies?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.